Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases

Br J Haematol. 2015 Mar;168(5):671-8. doi: 10.1111/bjh.13196. Epub 2014 Nov 2.

Abstract

This retrospective analysis was conducted in 64 patients diagnosed with type I cryoglobulinaemia (CG) followed at two French centres. Median follow-up was 6·75 years. CG was IgG in 60% and IgM in 40% of all cases and was asymptomatic in 16 patients (25%). Cold-triggered ischaemic skin manifestations were observed in 33 patients (51%). Neurological manifestations were observed in 15 patients and renal manifestations in 13. Most of the patients with necrotic purpura (14/16, P = 0·009) and renal manifestations (11/13, P = 0·057) had IgG CG. IgG CG was associated with monoclonal gammopathy of undetermined significance (MGUS), myeloma, chronic lymphocytic leukaemia and lymphoplasmocytic lymphoma in 18, 13, 5 and 2 patients, respectively. IgM CG was associated with MGUS and Waldenström macroglobulinaemia in 8 and 18 cases, respectively. One third of patients did not receive any specific treatment. Various treatments, including rituximab, were administered to 25/31 patients with IgG CG and 6/25 patients with IgM CG due to CG-related symptoms. Rituximab was ineffective in all cases associated with a predominantly plasmacytic proliferation. To conclude, type I CG has specific clinico-biological characteristics compared to type II CG. Furthermore, there are differences in terms of related manifestations between type I IgG and type I IgM CG.

Keywords: cryoglobulinaemia; monoclonal gammopathy.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Cryoglobulinemia* / blood
  • Cryoglobulinemia* / drug therapy
  • Cryoglobulinemia* / pathology
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G / blood*
  • Ischemia / blood
  • Ischemia / drug therapy
  • Ischemia / pathology
  • Kidney / pathology
  • Kidney Diseases / blood
  • Kidney Diseases / drug therapy
  • Kidney Diseases / pathology
  • Male
  • Paraproteinemias* / blood
  • Paraproteinemias* / drug therapy
  • Paraproteinemias* / pathology
  • Retrospective Studies
  • Rituximab
  • Skin / blood supply
  • Skin / pathology
  • Skin Diseases / blood
  • Skin Diseases / drug therapy
  • Skin Diseases / pathology
  • Waldenstrom Macroglobulinemia* / blood
  • Waldenstrom Macroglobulinemia* / drug therapy
  • Waldenstrom Macroglobulinemia* / pathology

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Immunoglobulin G
  • Rituximab